Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 40, Issue , 1997, Pages

  Sikic, Branimir I ^a   Fisher, George A ^a   Lum, Bert L ^a   Halsey, Joanne ^a   Beketic Oreskovic, Lidija ^a   Chen, Gang ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interactions; Modulation; Multidrug resistance; PSC 833

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYCLOSPORIN; DAUNORUBICIN; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; PACLITAXEL; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE;

BIOAVAILABILITY; BREAST CANCER; CANCER; COLORECTAL CANCER; CONFERENCE PAPER; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EXCRETION; DRUG URINE LEVEL; GENE EXPRESSION; HEPATOBILIARY SYSTEM; HISTOCHEMISTRY; HUMAN; KIDNEY CANCER; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; LEUKEMIA; LYMPHOMA; MODULATION; MULTIDRUG RESISTANCE; MUTATION; MUTATION RATE; MYELOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOSPORINS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEIN;

EID: 0030738096     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto M (1994) Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54:1355
2. Arceci R (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215
3. Barrand MA, Rhodes T, Center MS, Twentyman PR (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A:408
4. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) A phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 12:835
5. Beck WT (1990) Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 17:11
6. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI (1995) Decreased mutation rate for doxorubicin resistance and suppression of mdr1 gene activation by PSC 833. J Natl Cancer Inst 87:1593
7. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V (1985) Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 3:311
8. Bertrand Y, Capdeville R, Balduck N, Philippe N (1992) Cyclosporin A used to reverse drug resistance increases vincristine neurotoxicity. Am J Hematol 40:158
9. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226
10. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smythe JF, Brampton MH, Bleehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610
11. Brophy NA, Marie J-P, Rojas VA, Warnke RA, McFall PJ, Smith SD, Sikic BI (1994) Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: evaluation by four techniques. Leukemia 8:327
12. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphocytic leukemia cells at diagnosis. Blood 79:473
13. Chan H, Thorner P, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689
14. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608
15. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85
16. Chaudhary PM, Mechetner EB, Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735
17. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang H, Fojo AT (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073
18. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650
19. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695
20. Dahl GV, Grier H, Sikic B, Weinstein H, Arceci R (1994) Multidrug resistance (MDR) reversal utilizing mitoxantrone, etoposide and continuous infusion cyclosporin (MEC) in pediatric ANLL. In: Neth R (ed) Acute leukemias - Prognostic factors and treatment strategies. Springer, New York Berlin Heidelberg, p 490
21. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE (1989) Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73:747
22. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Dune BGM, Taylor CW, Miller TP, Salmon SE (1989) Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415
23. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729
24. Durie BG, Dalton WS (1988) Reversal of drug resistance in multiple myeloma with verapamil. Br J Haematol 68:203
25. Fisher GA, Sikic BI (1995) Clinical studies with modulators of multidrug resistance. In: Fisher GA, Sikic BI (eds) Drug resistance in clinical oncology and hematology. Hematology/Oncology Clinics of North America series, vol 9. Saunders, Philadelphia, p 363
26. Fisher GA, Brophy NA, Yahanda AM, Adler KA, Lum BL, Bartlett NL, Halsey J, Sikic BI (1993) The modulation of multidrug resistance: clinical studies at Stanford. In: Miyazaki T, Takaku F, Sakurada K (eds) The mechanism and new approach on drug resistance of cancer cells. Excerpta Medica, Amsterdam, p 255
27. Fojo AT, Shen D-W, Mickley LQ, Pastan I, Gottesman MM (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5:1922
28. Fojo A, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistant gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265
29. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F (1991) SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 2:225
30. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM (1987) P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5:1452
31. Goasguen JE, Dossot J-M, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R (1993) Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81:2394
32. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116
33. Gottesman M (1993) How cancer cells evade chemotherapy: 16th Richard and Linda Rosenthal Foundation Award Lecture. Cancer Res 53:747
34. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB (1992) Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84:1486
35. Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ (1989) Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 38:1727
36. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595
37. Jachez B, Nordmann R, Loor F (1993) Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporin SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85:478
38. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC (1992) Pharmacologic interactions between the resistance-modifying cyclosporin SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51:433
39. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18:239
40. Ling V (1992) Charles F. Kettering prize. P-glycoprotein and resistance to anticancer drugs. Cancer 69:2603
41. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futcher B, Baier M, Dalton W (1993) Phase I/II trial of cyclosporin as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11:1652
42. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635
43. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI (1993) Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considerations. Cancer 72:3502
44. Lum BL, Gosland MP, Kaubisch S, Sikic BI (1993) Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13:88
45. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586
46. Marie JP, Brophy NB, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, Sikic BI (1992) Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol 81:145
47. McLeod HL (1994) Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction. Eur J Cancer 30A:2039
48. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17
49. Miyashita T, Reed JC (1992) Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407
50. Miyashita T, Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood 81:151
51. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641
52. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126
53. Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, Baccarani M (1991) Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19:131
54. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708
55. Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F (1992) SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anticancer Drugs 3:419
56. Roninson IB (1991) Molecular and cellular biology of multidrug resistance in tumor cells. Plenum Press, New York
57. Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grunwald H, Gottlieb A, Bennet J, Gottesman M, Pastan I (1990) MDR1 transcripts levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 75:340
58. Scheper RJ, Broxterman HJ, Scheffer GL, Kaajjik P, Dalton WS, Heijningen THM van, Kalken CK van, Slovak ML, Vries EGE de, Valk P van der, Meijer CJLM, Pinedo HM (1993) Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475
59. Schinkel AH, Smit JJM, Tellingen O van, Beijnen JH, Wagenaar E, Deemter L van, Mol CAAM, Valk MA van der, Robanus-Maandag EC, Riele PJ te, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491
60. Schinkel AH, Mol CAAM, Wagenaar E, Deemter L van, Smit JJM, Borst P (1995) Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295
61. Schinkel AH, Wagenaar E, Deemter L van, Mol CAAM, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698
62. Sikic BI (1993) Modulation of multidrug resistance: at the threshold (editorial). J Clin Oncol 11:1629
63. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Lswenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255
64. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, Engineer FN (1992) Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 84:1653
65. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735
66. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967
67. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI (1992) A phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 10:1624